ENTA

Q3'20

Last Updated:

Enanta Pharmaceuticals

Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2.

Cash

$370.0M

Burn Rate (Quarterly)

$14.3M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

MAVYRET (Glecaprevir)

Hepatitis C Virus

Quarterly Sales (Approved)

February 5, 2021 (Est)

EDP-938

Respiratory Syncytial Virus (RSV)

Phase 2

Q4 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

ENTA - Enanta Pharmaceuticals ...

Summary: On track to initiate a Phase 2b study in adult transplant patients with respiratory syncytial virus by year-end and a Phase 2 study in pediatric patients with respiratory syncytial virus in e...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon